Why did ANI Pharmaceuticals (ANIP) stock move recently?

On 7/28/2026, ANI Pharmaceuticals moved +3.4% — No specific company catalyst identified for the move; ANIP rose with broader market or sector sentiment. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is ANI Pharmaceuticals (ANIP) overvalued or fairly valued?

MarketChacha shows ANI Pharmaceuticals's valuation in context — a trailing P/E of about 19.8, a forward P/E of about 7.2, a price-to-book of about 2.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does ANI Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (4.68×) from reported figures — education, not a rating.

What is ANI Pharmaceuticals's revenue?

ANI Pharmaceuticals reported revenue of $883.4M for FY2025, with net profit of $78.3M, per official filings.

What is the share price of ANI Pharmaceuticals (ANIP)?

ANI Pharmaceuticals last traded at $75.76 (-3.2% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

ANI Pharmaceuticals

ANIP · NYSE · Healthcare · United States

Snapshot

TickerANIP

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees970

HeadquartersBaudette, United States

Websitewww.anipharmaceuticals.com

Filings tracked20

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Who owns it

Insiders5.5%
Institutions94.5%
Public & other0.0%

400 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.13.01%
State Street Corporation3.66%
Vanguard Capital Management LLC3.62%
Soleus Capital Management, L.P.3.61%
Tang Capital Management, LLC3.11%
Goldentree Asset Management LP2.94%
Deep Track Capital, Lp2.64%
Millennium Management Llc2.60%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion4.68×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend3.9% → 8.9%

Margin has expanded by about 5.0 points — the business is getting more profitable.

Growth qualityrev 35% · PAT 104%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $321.1M · EPS 2.86

Est. earnings growth +22.7%

Next fiscal year

Rev $1.2B · EPS 10.55

Est. earnings growth +13.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$883.4M

Net margin

8.9%

ROE

14.5%

Revenue CAGR (2y)

+34.7%

Profit CAGR (2y)

+104.2%

EPS (FY2025)

3.32

Net profit (FY2025)

$78.3M

Ask MarketChacha about ANIP

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
No specific company catalyst identified for the move; ANIP rose with broader market or sector sentiment.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$883.4M	$78.3M	3.32	8.9%	14.5%
FY2024	$614.4M	$-18.5M	-1.04	-3.0%	-4.6%
FY2023	$486.8M	$18.8M	0.85	3.9%	4.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$266.0M	$24.7M	1.05	9.3%
2026Q1	$237.5M	$29.5M	1.28	12.4%
2025Q3	$227.8M	$26.6M	1.13	11.7%
2025Q2	$211.4M	$8.5M	0.36	4.0%
2025Q1	$197.1M	$15.7M	0.69	8.0%
2024Q3	$148.3M	$-24.2M	-1.27	-16.3%
2024Q2	$138.0M	$-2.3M	-0.14	-1.7%
2024Q1	$137.4M	$18.2M	0.82	13.2%
2023Q3	$131.8M	$9.9M	0.45	7.5%
2023Q2	$116.5M	$6.2M	0.29	5.4%
2023Q1	$106.8M	$1.4M	0.06	1.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/7/2026material
10-Q filing
SEC8/7/2026
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/21/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/13/2026material
8-K — Results of operations, Exhibits
SEC5/8/2026material
10-Q filing
SEC5/8/2026
8-K — Auditor change, Exhibits
SEC4/7/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/3/2026material
8-K — Results of operations, Exhibits
SEC2/27/2026material
10-K filing
SEC2/27/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC12/1/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/10/2025material
8-K — Results of operations, Exhibits
SEC11/7/2025material
10-Q filing
SEC11/7/2025
8-K — Unregistered equity sale, Security holder rights
SEC9/26/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC9/8/2025material
8-K — Results of operations, Exhibits
SEC8/8/2025material
10-Q filing
SEC8/8/2025
8-K — Other events
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.